Published in Oncogene on February 01, 1991
Cell cycle regulation of the human cdc2 gene. EMBO J (1992) 3.69
Human fibroblast commitment to a senescence-like state in response to histone deacetylase inhibitors is cell cycle dependent. Mol Cell Biol (1996) 1.78
WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol Cell Biol (1997) 1.68
Epstein-Barr virus nuclear antigen EBNA3C/6 expression maintains the level of latent membrane protein 1 in G1-arrested cells. J Virol (1994) 1.60
Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer. Annu Rev Pathol (2009) 1.20
Nuclear protein phosphorylation and growth control. Biochem J (1992) 1.16
Enhanced tumor cell growth suppression by an N-terminal truncated retinoblastoma protein. Proc Natl Acad Sci U S A (1994) 1.08
Dissociation of retinoblastoma gene protein hyperphosphorylation and commitment to enter S phase. J Virol (1994) 0.88
Proteomic and protein interaction network analysis of human T lymphocytes during cell-cycle entry. Mol Syst Biol (2012) 0.82
Fresh Garlic Extract Induces Growth Arrest and Morphological Differentiation of MCF7 Breast Cancer Cells. Genes Cancer (2012) 0.79
Transcriptional reprogramming in cellular quiescence. RNA Biol (2017) 0.75
Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med (1999) 3.88
Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol (2000) 2.29
Amplification of mitochondrial DNA in acute myeloid leukaemia. Br J Haematol (1996) 2.17
Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet (1996) 2.06
A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood (1999) 1.97
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood (2000) 1.93
Phytohaemagglutinin activation of T cells through the sheep red blood cell receptor. Nature (1985) 1.89
Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age. Br J Haematol (1997) 1.83
Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet (2003) 1.80
Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) (2006) 1.76
Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet (1990) 1.71
PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia (2005) 1.61
The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood (1993) 1.55
Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. N Engl J Med (1984) 1.54
TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia (2008) 1.50
Human macrophage colony-stimulating factor levels are elevated in pregnancy and in immune thrombocytopenia. Blood (1992) 1.49
Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice. Blood (1990) 1.47
Fc gamma RII, but not erythropoietin or GM-CSF, mediates calcium mobilization in fetal hemopoietic blast cells. Exp Hematol (1992) 1.45
Cushing's syndrome--killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet (1982) 1.45
Lack of effect of granulocyte-macrophage and granulocyte colony-stimulating factors on cultured human endothelial cells. Blood (1991) 1.43
Incidence and mechanism of neutropenia and thrombocytopenia in patients with human immunodeficiency virus infection. Br J Haematol (1987) 1.42
Investigation of early T cell activation: analysis of the effect of specific antigen, interleukin 2 and monoclonal antibodies on intracellular free calcium concentration. Eur J Immunol (1985) 1.41
X-chromosome inactivation patterns using HPRT and PGK polymorphisms in haematologically normal and post-chemotherapy females. Br J Haematol (1991) 1.39
Acute-phase response in patients given rhIL-3 after chemotherapy. Lancet (1992) 1.39
Tissue specificity of X-chromosome inactivation patterns. Blood (1994) 1.37
CD2 and CD3 antigens mobilize Ca2+ independently. Eur J Immunol (1986) 1.29
BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol (1995) 1.29
The genetic basis of autosomal dominant familial Mediterranean fever. QJM (2000) 1.29
Phenotypic analysis of fetal blood leucocytes: potential for prenatal diagnosis of immunodeficiency disorders. Prenat Diagn (1982) 1.28
Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol (1994) 1.28
Signal transduction in human T lymphocytes. Immunol Rev (1987) 1.21
Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism. Ann Rheum Dis (2006) 1.17
Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood (1989) 1.17
Different pathways of human T-cell activation revealed by PHA-P and PHA-M. Immunology (1986) 1.16
T cell receptor gene rearrangements define a monoclonal T cell proliferation in patients with T cell lymphocytosis and cytopenia. Blood (1986) 1.15
High incidence of Notch-1 mutations in adult patients with T-cell acute lymphoblastic leukemia. Leukemia (2006) 1.14
Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant (2008) 1.14
Dynamics of telomere shortening in neutrophils and T lymphocytes during ageing and the relationship to skewed X chromosome inactivation patterns. Br J Haematol (2000) 1.14
Phenotypic and molecular analysis of six human cell lines derived from patients with plasma cell dyscrasia. Br J Haematol (1999) 1.13
Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J Clin Oncol (2001) 1.12
Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials. MRC Adult Leukaemia Working Party. Br J Haematol (1997) 1.10
Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun (2004) 1.09
A second autologous transplant may be efficacious in selected patients with Hodgkin's lymphoma relapsing after a previous autograft. Leuk Lymphoma (2007) 1.08
Growth factor withdrawal from primary human erythroid progenitors induces apoptosis through a pathway involving glycogen synthase kinase-3 and Bax. Blood (2001) 1.07
The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. Leukemia (2013) 1.07
Activation of human monocytes occurs on cross-linking monocytic antigens to an Fc receptor. J Immunol (1989) 1.06
T cell disorders in haematological diseases. Clin Haematol (1982) 1.05
Prenatal diagnosis of three cases of severe combined immunodeficiency: severe T cell deficiency during the first half of gestation in fetuses with adenosine deaminase deficiency. Clin Exp Immunol (1984) 1.03
Molecular and functional characterisation of E2F-5, a new member of the E2F family. Oncogene (1995) 1.02
Clinical stage 1 non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer (1994) 1.02
Transient leucopenia induced by granulocyte-macrophage colony-stimulating factor. Lancet (1987) 1.02
Characterization of cell cycle status and E2F complexes in mobilized CD34+ cells before and after cytokine stimulation. Blood (1997) 1.01
The effect of mitogenic lectins and monoclonal antibodies on intracellular free calcium concentration in human T-lymphocytes. Biochem J (1984) 1.01
T cell regeneration after allogeneic and autologous bone marrow transplantation. Br J Haematol (1983) 0.99
Differential effects of granulocyte- and granulocyte-macrophage colony-stimulating factors (G- and GM-CSF) on neutrophil adhesion in vitro and in vivo. Eur J Haematol (1992) 0.98
Mechanism of human monocyte activation via the 40-kDa Fc receptor for IgG. J Immunol (1988) 0.98
The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group. Br J Haematol (1997) 0.98
Proto-oncogenic properties of the DP family of proteins. Oncogene (1995) 0.97
Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant. Blood (1988) 0.97
Selective peripheral blood eosinophilia associated with survival advantage in Hodgkin's disease (BNLI Report No 31). British National Lymphoma Investigation. J Clin Pathol (1987) 0.96
An erythrocyte membrane-protein anomaly in march haemoglobinuria. Lancet (1979) 0.94
Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet (1994) 0.94
Transmigration of CD34+ cells across specialized and nonspecialized endothelium requires prior activation by growth factors and is mediated by PECAM-1 (CD31). Blood (1998) 0.94
Frequency of CBF beta/MYH11 fusion transcripts in patients entered into the U.K. MRC AML trials. The MRC Adult Leukaemia Working Party. Br J Haematol (1997) 0.94
Prenatal diagnosis of immunodeficiency disorders. Br Med Bull (1983) 0.94
The relationship between mitogen-induced membrane potential changes and intracellular free calcium in human T-lymphocytes. Biochim Biophys Acta (1986) 0.94
Granulocyte-macrophage colony-stimulating factor induces neutrophil adhesion to pulmonary vascular endothelium in vivo: role of beta 2 integrins. Blood (1992) 0.93
The effects of pertussis toxin on human T lymphocytes. Immunology (1988) 0.93
In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. Cytotherapy (2001) 0.93
A case of EBV-associated lymphoproliferative disease following high-dose therapy and CD34-purified autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant (1998) 0.92
The morphology and cytochemistry of human T-cell subpopulations defined by monoclonal antibodies and Fc receptors. Br J Haematol (1982) 0.92
Cell cycle arrest of proliferating neuronal cells by serum deprivation can result in either apoptosis or differentiation. J Neurochem (1993) 0.92
Abnormalities of T-cell subsets in patients with neutropenia and an excess of lymphocytes in the bone marrow. Br J Haematol (1981) 0.92
Analysis of granulocyte colony stimulating factor receptor isoforms, polymorphisms and mutations in normal haemopoietic cells and acute myeloid leukaemia blasts. Br J Haematol (1996) 0.92
Influence of cell cycle phase-specific agents on simian fetal hemoglobin synthesis. J Clin Invest (1985) 0.91
Plasma from patients with severe Lassa fever profoundly modulates f-met-leu-phe induced superoxide generation in neutrophils. Br J Haematol (1989) 0.91
Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated patients with lymphoma. J Clin Oncol (1994) 0.91
Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation. Br J Haematol (2000) 0.91
Granulocyte macrophage colony stimulating factor induced changes in cellular adhesion molecule expression and adhesion to endothelium: in-vitro and in-vivo studies in man. Br J Haematol (1989) 0.91
Binding of monoclonal antibody to CD16 causes calcium mobilization in large granular lymphocytes but inhibits NK killing. Immunology (1989) 0.91
Leukaemia complicating treatment for Hodgkin's disease: the experience of the British National Lymphoma Investigation. BMJ (1990) 0.91
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. Br J Cancer (1999) 0.90
Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). Ann Oncol (2006) 0.90
Rapid prenatal diagnosis of adenosine deaminase deficiency and other purine disorders using foetal blood. Biosci Rep (1983) 0.90
Unusual T cell proliferations and neutropenia in rheumatoid arthritis: comparison with classical Felty's syndrome. Scand J Haematol (1984) 0.90
Studies of circulating hemopoietic progenitor cells in human fetal blood. Blood (1982) 0.90
Uptake of antibody directed cytotoxic liposomes by CD3 on human T cells. Clin Exp Immunol (1988) 0.90
Monoclonal antibodies differentiating between monocytic and nonmonocytic variants of AML. Blood (1984) 0.90
Membrane phenotype and response to deoxycoformycin in mature T cell malignancies. Br Med J (Clin Res Ed) (1987) 0.89
Assessment of X-chromosome inactivation patterns using the hypervariable probe M27 beta in normal hemopoietic cells and acute myeloid leukemic blasts. Leukemia (1992) 0.89
Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional-dose therapy. J Clin Oncol (1989) 0.89
Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial. Leukemia (2012) 0.88
Frequency of clonal remission in acute myeloid leukaemia. Lancet (1993) 0.88